United States Continuous Glucose Monitoring (CGM) Market Worth US$ 8.4 Billion by 2033 Exclusive Report by DPI Research

January 20, 2025 06:37 PM AEDT | By EIN Presswire
 United States Continuous Glucose Monitoring (CGM) Market Worth US$ 8.4 Billion by 2033 Exclusive Report by DPI Research
Image source: EIN Presswire

Comprehensive Analysis of the US Market Size and Growth Rate for Continuous Glucose Monitoring (CGM) vs. Blood Glucose Meters (BGM) (2021–2033) NEW DELHI, DELHI, INDIA, January 18, 2025 /EINPresswire.com/ -- The United States Continuous Glucose Monitoring (CGM) market size was valued at USD 3.7 billion in 2024 and is projected to hit around USD 8.4 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025 to 2033.

United States Continuous Glucose Monitoring (CGM) Market Growth Drivers

One of the primary drivers fuelling the growth of the CGM market in the United States is the rising prevalence of diabetes. According to recent statistics, millions of Americans are diagnosed with diabetes each year, leading to a growing need for effective monitoring solutions. Additionally, increasing health awareness and technological advancements in sensor technology have encouraged more patients and healthcare providers to turn to CGM systems.

United States Continuous Glucose Monitoring (CGM) Market Synopsis

This market report is based on an inclusive study of the entire United States Continuous Glucose Monitoring (CGM) market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States Continuous Glucose Monitoring (CGM) market. The study also presents a comprehensive analysis of the market dynamics and estimation of the market size over the forecast period. The report delivers a clear understanding of the up-to-date and future growths of the United States Continuous Glucose Monitoring (CGM) market.

The report contains a granular analysis of the present industry situations and market demands, revealing facts on the market size, volume, revenues for Continuous Glucose Monitoring (CGM), and an illustrative forecast for 2033. The report also provides an all-around analysis of the overall number of patients with diabetes and insulin users in the United States. An all-inclusive examination has been done on the pricing, demand, and key development of the Continuous Glucose Monitoring (CGM) market in the United States. The report also reveals facts, statistics, growth rate, and demand of the Continuous Glucose Monitoring (CGM) vs. Blood Glucose Meter (BGM) market in the United States. A comprehensive comparative analysis has been done on continuous glucose monitoring devices.

Additionally, this up-to-date report describes the latest features of the reimbursement pattern and offers a clear view of the regulatory framework of the United States Continuous Glucose Monitoring (CGM) market. Key trends in terms of collaboration and partnership deals are analyzed in detail. The report also delivers an in-depth analysis of evolving SWOT analysis, market trends, drivers, and restraining forces that influence the growth of the market.

The report also analyses detailed profiles of innovative and leading players with information on business overview, product portfolio, and the latest developments. Other emerging players are making novel technology-based continuous glucose monitoring (CGM) that are likely to affect the market share during the forecast period.

Some of the Prominent Players in the United States Continuous Glucose Monitoring (CGM) Market

The Continuous Glucose Monitoring (CGM) market in the United States is characterized by the presence of several key players, each contributing significantly to the growth and innovation within the industry. Notably, Dexcom, Abbott Laboratories, Medtronic Inc., and Senseonics Holdings, Inc. are recognized as leading companies that have established themselves as formidable competitors in this evolving landscape.

Dexcom is a prominent player in the CGM market, known for its innovative glucose monitoring systems. Their flagship product, the Dexcom G7, provides real-time glucose data and requires no fingerstick calibration, making it a favorite among patients and healthcare professionals alike. The company has consistently focused on improving user experience and accuracy, which has solidified its position in the market. Dexcom’s strategic partnerships with healthcare providers and insurance payers have enhanced its accessibility and adoption rates.

Another essential competitor, Abbott Laboratories, offers the FreeStyle Libre system, which has gained immense popularity due to its simplicity and ease of use. The FreeStyle Libre provides users with a streamlined experience for tracking glucose levels without the need for finger pricks. Abbott’s commitment to continuous innovation is evident in its investment in expanding its product line, such as the recently launched FreeStyle Libre 2, which features optional real-time alarms for users to monitor their glucose levels more effectively.

Medtronic rounds out the trio of key players, distinguished for integrating advanced technology into its CGM products. The Medtronic Guardian Connect system not only monitors glucose levels but also utilizes predictive algorithms to forewarn users of impending glucose fluctuations. The company’s strategic focus on combining insulin delivery with CGM technology ensures that they remain a strong contender in the market, highlighting their approach to seamless diabetes management.

These companies are continually working to differentiate themselves through unique product offerings, technological advancements, and strategic collaborations, ensuring a competitive and growing CGM market in the United States.

Report Scope of the United States Continuous Glucose Monitoring (CGM) Market

To Examine the Past Development of the US Continuous Glucose Monitoring (CGM) Market Size from 2021 to 2024
Assessing and Projecting the US Continuous Glucose Monitoring (CGM) Market Size and Growth Rate from 2025 to 2033
An in-depth analysis of the number of continuous glucose monitoring (CGM) users in the US and its projections through 2033
Comprehensive Analysis of the US Market Size and Growth Rate for Continuous Glucose Monitoring (CGM) vs. Blood Glucose Meters (BGM) (2021–2033)
Provides Detailed Information on the Comparison of Continuous Glucose Monitoring Devices
A Comprehensive Study of Diabetes in the United States and Its Prognosis Through 2033
Delivers a Complete Overview of the United States Insulin Users and Forecast to 2033
Comprehensive Analysis of the US Continuous Glucose Monitoring (CGM) Market’s Regulatory Environment
Characteristics of the US Continuous Glucose Monitoring (CGM) Market Reimbursement Patterns
SWOT analysis of continuous glucose monitoring (CGM) in the United States
Provides a Comprehensive Examination of Changing Market Trends, Growth Drivers, and Obstacles in the US Continuous Glucose Monitoring (CGM) Industry
Tracks Competitive Developments, Approaches, Recent Industry Developments, Collaboration Deals, and Partnership Deals
A thorough list of the major players, along by an analysis of their recent developments, business overviews, and current product portfolios

More Details about this report: https://dpiresearch.com/report/continuous-glucose-monitoring-cgm-market-in-the-us-2025-2033/

Mansur Ansari
DPI Research
email us here
+91 76676 48693
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.